` NRIX (Nurix Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

NRIX
vs
S&P 500

Over the past 12 months, NRIX has underperformed S&P 500, delivering a return of -49% compared to the S&P 500's +13% growth.

Stocks Performance
NRIX vs S&P 500

Loading
NRIX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
NRIX vs S&P 500

Loading
NRIX
S&P 500
Difference
www.alphaspread.com

Performance By Year
NRIX vs S&P 500

Loading
NRIX
S&P 500
Add Stock

Competitors Performance
Nurix Therapeutics Inc vs Peers

S&P 500
NRIX
ABBV
AMGN
GILD
VRTX
Add Stock

Nurix Therapeutics Inc
Glance View

Market Cap
856.8m USD
Industry
Biotechnology

Nestled in the heart of the biotechnology wave, Nurix Therapeutics Inc. emerges as a pioneer in the burgeoning field of protein modulation. Founded with the ambition to transform drug discovery, the company focuses on manipulating the body’s complex system of protein degradation. Their mission orbits around harnessing the ubiquitin-proteasome system, a natural cellular process responsible for degrading unwanted proteins. Through this sophisticated dance of molecule manipulation, Nurix endeavors to tackle diseases that have eluded traditional drug discovery methods, aiming to control the fate of disease-causing proteins within the cellular ecosystem. Nurix’s business model thrives on a dual approach: proprietary drug development and strategic collaborations. The company pursues its own pipeline of novel therapeutics targeting oncology and immunology, seeking breakthroughs that could redefine treatments for cancer and immune-related diseases. Simultaneously, it partners with pharmaceutical giants, leveraging its DUB (Deubiquitinase) platform technology in exchange for upfront payments, research funding, and potential milestones. This hybrid strategy not only diversifies their revenue streams but also amplifies their scientific influence, positioning them as a vital contributor to the evolving landscape of biopharmaceutical innovation. Through these finely-tuned processes, Nurix crafts its path in the highly competitive biotech arena, striving to turn cutting-edge science into tangible healthcare solutions.

NRIX Intrinsic Value
9.47 USD
Overvaluation 16%
Intrinsic Value
Price
Back to Top